TY - JOUR
T1 - Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy
T2 - Prospective self-controlled trial
AU - Hanai, Akiko
AU - Ishiguro, Hiroshi
AU - Sozu, Takashi
AU - Tsuda, Moe
AU - Yano, Ikuko
AU - Nakagawa, Takayuki
AU - Imai, Satoshi
AU - Hamabe, Yoko
AU - Toi, Masakazu
AU - Arai, Hidenori
AU - Tsuboyama, Tadao
N1 - Publisher Copyright:
© The Author 2017.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention. Methods: Breast cancer patients treated weekly with paclitaxel (80mg/m 2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides. The primary end point was CIPN incidence assessed by changes in tactile sensitivity from pretreatment baseline in a monofilament test at a cumulative dose of 960mg/m2.We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire [PNQ]), manipulative dexterity, and the time to events and hazard ratio by PNQ. All statistical tests were two-sided. Results: Among the 40 patients, four did not reach the cumulative dose (due to the occurrence of pneumonia, severe fatigue, severe liver dysfunction, and macular edema), leaving 36 patients for analysis. None dropped out due to cold intolerance. The incidence of objective and subjective CIPN signs was clinically and statistically significantly lower on the intervention side than on the control (hand: tactile sensitivity = 27.8% vs 80.6%, odds ratio [OR] = 20.00, 95% confidence interval [CI] = 3.20 to 828.96, P < .001; foot: tacile sensitivity = 25.0% vs 63.9%, OR = infinite, 95% CI=3.32 to infinite, P < .001; hand: warm sense = 8.8% vs 32.4%, OR=9.00, 95% CI=1.25 to 394.48, P = .02; foot: warm sense: 33.4% vs 57.6%, OR=5.00, 95% CI=1.07 to 46.93, P = .04; hand: PNQ = 2.8% vs 41.7%, OR = infinite, 95% CI=3.32 to infinite, P < .001; foot: PNQ = 2.8% vs 36.1%, OR = infinite, 95% CI=2.78 to infinite, P < .001; hand: hazard ratio [HR] = 0.13, 95% CI=0.05 to 0.34; foot: HR=0.13, 95% CI=0.04 to 0.38, dexterity mean delay= -2.5 seconds, SD=12.0 seconds, vs+8.6 seconds, SD=25.8 seconds, P = .005). Conclusions: Cryotherapy is useful for preventing both the objective and subjective symptoms of CIPN and resultant dysfunction.
AB - Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention. Methods: Breast cancer patients treated weekly with paclitaxel (80mg/m 2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides. The primary end point was CIPN incidence assessed by changes in tactile sensitivity from pretreatment baseline in a monofilament test at a cumulative dose of 960mg/m2.We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire [PNQ]), manipulative dexterity, and the time to events and hazard ratio by PNQ. All statistical tests were two-sided. Results: Among the 40 patients, four did not reach the cumulative dose (due to the occurrence of pneumonia, severe fatigue, severe liver dysfunction, and macular edema), leaving 36 patients for analysis. None dropped out due to cold intolerance. The incidence of objective and subjective CIPN signs was clinically and statistically significantly lower on the intervention side than on the control (hand: tactile sensitivity = 27.8% vs 80.6%, odds ratio [OR] = 20.00, 95% confidence interval [CI] = 3.20 to 828.96, P < .001; foot: tacile sensitivity = 25.0% vs 63.9%, OR = infinite, 95% CI=3.32 to infinite, P < .001; hand: warm sense = 8.8% vs 32.4%, OR=9.00, 95% CI=1.25 to 394.48, P = .02; foot: warm sense: 33.4% vs 57.6%, OR=5.00, 95% CI=1.07 to 46.93, P = .04; hand: PNQ = 2.8% vs 41.7%, OR = infinite, 95% CI=3.32 to infinite, P < .001; foot: PNQ = 2.8% vs 36.1%, OR = infinite, 95% CI=2.78 to infinite, P < .001; hand: hazard ratio [HR] = 0.13, 95% CI=0.05 to 0.34; foot: HR=0.13, 95% CI=0.04 to 0.38, dexterity mean delay= -2.5 seconds, SD=12.0 seconds, vs+8.6 seconds, SD=25.8 seconds, P = .005). Conclusions: Cryotherapy is useful for preventing both the objective and subjective symptoms of CIPN and resultant dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=85049649028&partnerID=8YFLogxK
U2 - 10.1093/jnci/djx178
DO - 10.1093/jnci/djx178
M3 - Article
C2 - 29924336
AN - SCOPUS:85049649028
SN - 0027-8874
VL - 110
SP - 141
EP - 148
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -